Ionis Pharmaceuticals Inc. announced positive results from its pivotal Phase 3 CORE and CORE2 studies evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG). The studies met their primary endpoint, demonstrating a placebo-adjusted mean reduction in fasting triglyceride levels of up to 72% at six months, with reductions sustained through 12 months. Olezarsen also achieved an 85% reduction in acute pancreatitis events and enabled 86% of treated patients to reach triglyceride levels below 500 mg/dL, which is below the risk threshold for acute pancreatitis. The drug showed a favorable safety and tolerability profile, as well as significant improvements in secondary lipid endpoints. These results were presented during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and were published in The New England Journal of Medicine.